Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(65)
•••
Comment by Kusanationon Jul 30, 2020 9:15pm
139 Views
Post# 31347420

RE:RE:RE:RE:RE:RE:RE:Has anyone ...

RE:RE:RE:RE:RE:RE:RE:Has anyone ...Rick,

Very well said. I agree with you, Dan really needs to give his input and clear a lot of this up. It very well could be that he is in talks and needs to be tight liped. I just don't think the letter to shareholders will say anything exceptional like some are hoping and like Dan may have alluded to. Don't get your hopes up is my answer. No, it won't be bad but I'm expecting this stock to pop after his letter. Be prepared to face a RS announcement at the AGM. I've invested in companies that have done this and the AGM has almost always been the event they used to express their intent to excersize that option. We will good at the end of the day but don't expect this to be a "Kodak moment" haha get it? (for those who understand Kodaks surge yesterday). Anyway, good luck to all, hopefully we got bought out soon!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities